“Modest” Results With Nitazoxanide for HCV Genotype 1 Nonresponders, Virginia Commonwealth University Study

MedScape -- April 27, 2010 (Vienna, Austria) — Adding nitazoxanide (Alinia, Romark Laboratories) to standard therapy helped boost sustained virologic response (SVR) rates for some hepatitis C virus (HCV) genotype 1 patients who previously failed to respond to standard therapy alone, researchers report.